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St Thomas’ NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK; 4Department of Clinical Oncology, Guys Hospital,
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Background: Although comorbidities are identified in routine oncology practice, intervention plans for the coexisting needs of
older people receiving chemotherapy are rarely made. This study evaluates the impact of geriatrician-delivered comprehensive
geriatric assessment (CGA) interventions on chemotherapy toxicity and tolerance for older people with cancer.
Methods: Comparative study of two cohorts of older patients (aged 70þ years) undergoing chemotherapy in a London Hospital.
The observational control group (N¼ 70, October 2010–July 2012) received standard oncology care. The intervention group
(N¼ 65, September 2011–February 2013) underwent risk stratification using a patient-completed screening questionnaire and
high-risk patients received CGA. Impact of CGA interventions on chemotherapy tolerance outcomes and grade 3þ toxicity rate
were evaluated. Outcomes were adjusted for age, comorbidity, metastatic disease and initial dose reductions.
Results: Intervention participants undergoing CGA received mean of 6.2±2.6 (range 0–15) CGA intervention plans each. They
were more likely to complete cancer treatment as planned (odds ratio (OR) 4.14 (95% CI: 1.50–11.42), P¼ 0.006) and fewer required
treatment modifications (OR 0.34 (95% CI: 0.16–0.73), P¼ 0.006). Overall grade 3þ toxicity rate was 43.8% in the intervention
group and 52.9% in the control (P¼ 0.292).
Conclusions: Geriatrician-led CGA interventions were associated with improved chemotherapy tolerance. Standard oncology care
should shift towards modifying coexisting conditions to optimise chemotherapy outcomes for older people.
The number of clinically complex older people presenting to
cancer services is increasing. There are often concerns that older,
more comorbid or frail people may struggle to tolerate chemother-
apy. This may result in chemotherapy not being offered or in
planned treatment being modified or stopped early with potential
negative implications for prognosis (Foote, 1998).
Strategies are sometimes used to reduce toxicity risk, for
example, adapted treatment regimens (Schaich et al, 2002; Zinzani
et al, 2002; Basso et al, 2008; Kotsori et al, 2010) or using
granulocyte colony-stimulating factor (Repetto et al, 2003; Brugger
et al, 2009). These strategies focus on adapting treatment and
rarely include optimising patient factors (e.g. comorbidity,
function) that may influence chemotherapy toxicity and/or
tolerance (Wedding et al, 2007). Although oncology assessments
include identifying patient factors to inform cancer treatment
decisions (Blanco et al, 2008; Ring, 2008; Department of Health, 2012a),
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this assessment is rarely used to identify coexisting needs that may
be modified by clinical interventions (Extermann and Hurria,
2007; Maas et al, 2007).
Comprehensive geriatric assessment (CGA) is the central
technology of specialist geriatric medical practice. It involves a
review of frailty, comorbidities, geriatric syndromes (e.g. falls,
incontinence), mental health, functional difficulties and social
circumstances. Although the term CGA may imply activity limited
to assessment, it is in fact a larger clinical process with four parts:
(1) screening, (2) assessment (including standardised tools to
augment clinical history and examination), (3) goal-directed
intervention and (4) follow through (Rubenstein et al, 1991). All
parts of this process are integral to delivering evidence-
based CGA.
Comprehensive geriatric assessment has a robust evidence base
of effectiveness in several clinical settings: improved function and
reduced institutionalisation in community-dwelling individuals
(Stuck et al, 1993); similar benefits plus reduced mortality in older
medical in-patients (Stuck et al, 1993; Ellis et al, 2011a, b),
and reduced postoperative complications, shorter length of
hospital stay and reduced mortality in orthopaedics and other
surgery (Elliot et al, 1996; Harari et al, 2007; Gonzalez Montalvo
et al, 2011).
Studies of CGA in the cancer literature have generally reported
evaluations limited to the screening and/or assessment part of the
CGA process, with assessment being largely tool-based (e.g.
nutritional screening tool, cognitive score) without a comprehen-
sive clinical review. Cancer studies including key elements of CGA,
namely clinical review, intervention and follow through, are
lacking (Wildiers et al, 2014). The differences between the
evidence-based CGA clinical process and these more limited
studies in the cancer literature were acknowledged in the recently
published International Society of Geriatric Oncology (SIOG)
consensus (Wildiers et al, 2014). International Society of Geriatric
Oncology renamed the term CGA as ‘GA’ to reflect this disparity.
Findings from studies investigating GA are difficult to compare
with those of CGA given the lack of clinical intervention with GA.
Studies of GA in oncology have evaluated feasibility as a
screening tool (Hurria et al, 2007) and influence on cancer
treatment decision-making (Girre et al, 2008; Marenco et al, 2008).
Some report its utility in predicting chemotherapy toxicity
(Extermann et al, 2011; Hurria et al, 2011). The few studies
investigating CGA show influence on improved survival following
cancer surgery (McCorkle et al, 2000), influence on oncological
decision-making, and that multiple CGA interventions are
required in cancer populations (Caillet et al, 2011; Chaibi et al,
2011). To the authors knowledge however, there are no studies
evaluating whether CGA, the clinical process (screening, assess-
ment, intervention, follow through), influences tolerance to
chemotherapy. The International Society of Geriatric Oncology
recently highlighted the need for such studies (Wildiers et al,
2014), reiterated by UK national health policies now advocating
comprehensive assessments for older people (based on the strong
evidence for CGA in other settings) at the time of cancer treatment
decision-making (Department of Health, 2010, 2012b).
The purpose of this study was to evaluate the impact of
geriatrician-delivered CGA on chemotherapy toxicity and toler-
ance. A secondary aim was to evaluate the number of interventions
required and made as a result of CGA in older people undergoing
chemotherapy.
MATERIALS AND METHODS
Study design. A prospective cohort comparison study, comparing
geriatrician-delivered CGA with usual oncology care.
Setting. The study was conducted in a London hospital providing
cancer care to patients living locally and across South-East
England. As with most UK hospitals, geriatricians and oncologists
work within their own disciplines in the same hospital, but with no
formal liaison between the two services. The service model to
deliver geriatrician-led CGA was developed for the purposes of this
study with stakeholder support from oncologists, nursing,
therapies, voluntary organisations and executive management. It
was based on existing CGA evidence and additionally moulded
from insights derived during the early stages of the observational
cohort study.
Participants. Participants included in this analysis were older
patients (aged 70þ years) with cancer recruited at the start of
chemotherapy (with or without radiotherapy). Potential partici-
pants were identified from oncology clinics and chemotherapy day
units using the hospital electronic record system.
Exclusion criteria
 Age o70 years.
 Cancer treatment plan excluded chemotherapy.
 Chemotherapy had already started before they could be
approached for participation.
 Lack of mental capacity to consent.
 Expected prognosis p3 months.
Control and intervention study recruitment periods crossed,
minimising potential period effect bias (control group October
2010–July 2012, intervention group September 2011–February
2013). This report is restricted to participants aged 70þ years
recruited at the start of chemotherapy within two larger studies
(one observational, one interventional) recruiting older people
presenting to cancer services. The overall observational study was
designed to identify comorbidities and CGA characteristics (using
a CGA questionnaire) associated with poorer treatment tolerance
in participants aged 65þ years receiving usual care. The overall
intervention study aimed to investigate the impact of CGA
interventions on cancer outcomes (including treatment tolerance
and survival) in participants aged 70þ years. Both these studies
included participants receiving a number of different treatment
modalities including but not restricted to chemotherapy (i.e. also
included surgical patients, radiotherapy, hormonal treatment, and
so on). We report the outcomes of those recruited at the start of
chemotherapy treatment, comparing the CGA intervention to
usual care. Patients excluded from the presented analysis either
received a non-chemotherapy treatment modality, were not recruited
at the start of chemotherapy or were not aged 70þ years in the
control group (to age match to the intervention group). Local
and national ethics approval was obtained for the observational
(09/H0178/65) and intervention study (11/LO/0695). All participants
gave written informed consent for participation.
Interventions. All participants (control and intervention) com-
pleted a baseline self-reported screening questionnaire (called
‘CGA-GOLD’) containing evidence-based CGA questions (Chen
et al, 2003; Terret et al, 2004; Hurria et al, 2005, 2007; Mohile et al,
2007) and a validated quality of life tool (QOL) (EORTC-QLQ-
C30) (Aaronson et al, 1993) (questionnaire available in online
Supplementary Material). The 70 control group participants
received routine care only. Their CGA-GOLD responses were
not shared with the oncology team. For the 65 intervention cohort
participants, the CGA-GOLD questionnaire was used to stratify
them into low or high risk. Low risk was defined as no self-
reported active comorbidities, CGA issues or recent hospital
admissions and ‘no’ or ‘little’ difficulties reported for all function
and QOL questions. High risk was defined as 1þ reported active
comorbidity and/or CGA issues and/or significant QOL/functional
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difficulties (self-reported as ‘quite a bit’ or ‘very much’ difficulty).
Additionally, telephone calls were made to clarify the need for
high-risk patients with p2 identified issues where the clinician
anticipated it may be possible to manage these without full CGA.
The telephone call either confirmed risk and need for CGA or
identified that these few issues were already managed or could be
managed remotely (e.g. dietitian referral for weight loss). Higher
risk patients received CGA before commencing chemotherapy. The
oncologist could additionally directly refer patients for CGA if they
deemed it was clinically indicated. Figure 1 summarises the risk
assessment pathway used for identifying those requiring CGA.
Comprehensive geriatric assessment covered domains as high-
lighted in the SIOG consensus (Wildiers et al, 2014). This included
a full medical assessment, comorbidity management (e.g. diabetes,
cardiac), management of geriatric syndromes (e.g. falls, incon-
tinence) and review of functional and psychosocial difficulties.
Cancer diagnosis, planned chemotherapy type and anticipated
toxicities were taken into consideration when decisions were made
regarding the need or type of intervention for a particular
comorbidity or CGA issue. For example, tighter diabetic control,
monitoring and pre-emptive plans for those to receive steroids
with chemotherapy vs looser control if poor oral intake anticipated
or not relevant in light of overall prognosis. Intervention plans
were made for CGA/comorbidities identified as modifiable. Issues
identified but not requiring interventions (either already being
addressed or already optimised or not modifiable) were not
included as interventions. The assessment and intervention plans
were communicated to the oncologist (electronically) before
starting chemotherapy, General Practitioner and patient. Further
geriatrician support and follow through was available as needed.
There were no other changes to oncology services during the study
period.
Measures. Patient demographics, comorbidities, cancer-related data
and outcomes were collected using hospital electronic patient records.
Twenty-three CGA variables were collected predominantly through
the CGA-GOLD questionnaire (comorbidity and CGA variable
definitions available in online Supplementary Material).
The impact of CGA on chemotherapy tolerance and toxicity was
evaluated by comparing the intervention and control cohorts as
follows:
Coprimary outcomes:
 Grade 3–5 toxicity rate (National Cancer Institute Common
Toxicity Criteria for Adverse events (CTCAE) version 4).
 Rate of completion of cancer treatment as planned (defined as
completing initially planned chemotherapy course without later
modifications or early discontinuation).
Secondary outcomes:
 Treatment modifications (delays and/or dose reductions and/or
drug omissions).
 Early treatment discontinuation.
 Dose escalations.
 Death at 6 months.
Completing treatment as planned was chosen as a coprimary
outcome because of the causal hypothesis of impact on disease
outcomes, plus observational work in the control group identified
that some patients have treatment modified/stopped for lower
grade toxicities (Kalsi et al, 2014a). Patients receiving neoadjuvant
and adjuvant chemotherapy had only one of these schedules
assessed for toxicity (closest to recruitment date) to avoid
contamination of chemotherapy toxicity by postoperative side
effects. Follow-up was for 6 months, or for those who died before
this, up to the point they died. The types and number of
interventions resulting from CGA were evaluated to answer the
secondary aim.
Statistical analysis. Univariate associations were identified using
independent T-test for comparing means, w2 or Fisher’s exact test
for comparing categorical data. Confounder bias was minimised
with logistic regression by adjusting for age plus other relevant
differences between the groups (comorbidity, metastatic disease,
chemotherapy dose reduction at the outset) in bivariate and
multivariate analysis.
For clinical service logistical reasons, the intervention targeted
gastrointestinal (GI) and urology patients, thus the range of
tumour type was broader in the control. There is no widely
accepted method to group different tumour types together for the
purpose of statistical analysis; therefore, to ensure outcome
CGA-GOLD risk
assessment
CGA-GOLD questionnaire 
N = 65
Received geriatrician-led CGA
N = 46
CGA
referral
N = 17
No CGA
referral
N = 18
High risk – needs CGA
N = 35
Low risk – no need for CGA
N = 19
CGA
N = 35
CGA
N = 5
CGA
referral
N = 5
No CGA
referral
N = 14
Maybe risk – needs clarification
N = 11
CGA
referral
N = 3
No CGA referral
N = 8
Telephone call – no
needs for CGA
N = 5
Telephone call
– needs CGA
N = 3
CGA
N = 6
Oncologist risk
assessment
Telephone clarification
of need if applicable
Received CGA in each
risk group
Received CGA whole
cohort
Figure 1. Risk assessment pathway used for identifying those requiring CGA in the intervention cohort.
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differences were not related to tumour type, the largest single
homogenous tumour group (GI) was examined separately.
RESULTS
A total of 135 participants (70 control, 65 intervention) were
included with 33 control and 41 intervention participants in the GI
subgroup.
Demographic, cancer, treatments, comorbidities and CGA
characteristics. Table 1 compares patient and cancer-related
characteristics. The control and intervention cohorts were largely
well matched except for comorbid burden, metastatic disease and
initial dose reductions at the outset (adjusted for in the later
analysis). Thirty different chemotherapy regimens were given
across the two cohorts. There were no differences in types of
comorbidities and CGA characteristics, except for more diabetes
(27.7% vs 13.2%, P¼ 0.038) and polypharmacy (50.8% vs 31.7.%,
P¼ 0.029) in the intervention cohort and more difficulties with
family and social activities in the control group (Table 2).
Interventions. Following risk assessment, CGA was required for
70.7% (46/65) of intervention subjects, with 97.8% requiring Z1
intervention plan. The mean number of CGA interventions per
patient was 6.2±2.6, median 6 and range 0–15. Nineteen low-risk
patients were not seen for CGA, but 36.8% (7/19) required a total
of 16 interventions arranged, mainly for fatigue (6), nutrition (4)
and anaemia (4). A total of 299 intervention plans were made for
the intervention cohort (see Table 3).
Outcomes and toxicity characteristics. The most common grade
3þ toxicities are summarised in Table 4. Outcomes were adjusted
for differences between cohorts (age, comorbidity, metastatic
disease and initial dose reductions). There was a nonsignificant
trend for a lower grade 3þ toxicity rate in the intervention cohort
(43.8% vs 52.9%, P¼ 0.292; Table 5). More participants in the
intervention group completed treatment as planned (33.8% vs
11.4%, odds ratio (OR) 4.14, P¼ 0.006) and fewer required
treatment modifications (43.1% vs 68.6%, OR 0.34, P¼ 0.006) after
adjustment for confounders (Table 5). Similar positive outcomes
were observed in the GI subgroup. Intervention participants had a
nonsignificant trend towards fewer discontinuing treatment early
(40.0% vs 51.4%, OR 0.63, P¼ 0.183). There were no differences in
Table 1. Patient, cancer and treatment characteristics
Whole cohort GI subgroup
Control %
(N¼70)
Intervention %
(N¼65) P-value
Control %
(N¼33)
Intervention %
(N¼41) P-value
Age
Mean 74.9±3.8 75.8±4.5 0.250 74.2±3.4 76.2±4.8 0.046
Median 74 75 73 75
Range 70–86 70–90 70–82 70–90
Sex and ethnicity
Male 50.0% (35/70) 60.0% (39/65) 0.243 63.6% (21/33) 51.2% (21/41) 0.284
Caucasian 88.1% (59/67) 82.5% (52/63) 0.373 84.4% (27/32) 82.1% (32/39) 0.795
Performance status
PS 0–1 73.5% (50/68) 83.3 (50/60) 0.181 84.4% (27/32) 89.7% (35/39) 0.722
PS 2–3 26.5% (18/68) 16.7 (10/60) 15.6% (5/32) 10.3% (4/39)
Cancer type
GI cancer 47.1% (33/70) 63.1% (41/65) 0.063 100% (33/33) 100% (41/41) NA
Other cancer 52.9% (37/70) 36.9% (24/65) 0 0
Cancer stage
Non-metastatic 40.0% (28/70) 56.9% (37/65) 0.049 51.5% (17/33) 56.1% (23/41) 0.694
Metastatic 60.0% (42/70) 43.1% (28/65) 48.5% (16/33) 43.9% (18/41)
Treatment intent
Curative/neoadjuvant/adjuvant 40.0% (28/70) 50.8% (33/65) 0.209 54.5% (18/33) 61.0% (25/41) 0.577
Palliative 60.0% (42/70) 49.2% (32/65) 45.5% (15/33) 39.0% (16/41)
Number of chemoagents
Monochemotherapy 41.4% (29/70) 36.9% (24/65) 0.592 39.4% (13/33) 31.7% (13/41) 0.491
Polychemotherapy 58.6% (41/70) 63.1% (41/65) 60.6% (20/33) 68.3% (28/41)
Other chemotherapy characteristics
Mean cycles delivered (range) 3.8±2.8 (range 1–12) 4.2±2.6 (range 1–12) 0.446 4.0±3.6 4.1±2.7 0.903
Median cycles delivered 3 4 3 4
With RT 18.6% (13/70) 10.8% (7/65) 0.202 30.3% (10/33) 17.1% (7/41) 0.179
Reduced dose at outset 20.0% (14/70) 40.0% (26/65) 0.011 18.2% (6/33) 36.6% (15/41) 0.081
Mean % dose reduction at the outset where
applicable
25.4±10.3 24.3±7.9 0.730 21.7±7.3 25.5±8.6 0.391
Median % dose reduction at the outset where
applicable
25 25 25 25
GCSF at outset 4.3% (3/70) 6.2% (4/65) 0.711 3.0% (1/33) 0 0.446
Comorbidities
Mean 2.9±1.8 3.9±2.1 0.004 2.9±1.7 3.9±2.3 0.061
Median 3.0 4.0 3.00 4.00
Range 0–8 0–10 0–8 0–10
Abbreviations: GCSF, granulocyte-colony-stimulating factor; GI¼gastrointestinal; NA¼ not applicable; PS¼performance status; RT¼ radiotherapy. Note: All percentages are calculated
excluding missing data. Bold highlights those numbers reaching statistical significance for differences between the control and intervention groups.
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all-cause death rates at 6 months (20.0% control, 15.4%
intervention, P¼ 0.483).
DISCUSSION
This comparative study demonstrated that geriatrician-delivered
CGA was associated with better outcomes for older people
undergoing chemotherapy. More intervention participants com-
pleted treatment as planned and required fewer treatment
modifications. There was a nonsignificant trend for fewer in the
intervention group to develop grade 3þ toxicity. Although this did
not reach statistical significance (possibly relating to small sample
size), the observed differences were sufficient to warrant further
investigation in future larger studies. To detect a 10% difference in
grade 3þ toxicity at 80% power, a sample size of 305 in each
group would be required.
The CGA-GOLD questionnaire and referrals to the geriatrician
were used as risk assessment tools to identify those needing CGA.
In a previous related work, CGA-GOLD demonstrated feasibility
with a mean completion time of 11.7min, completion without
assistance in 86.3% (Kalsi et al, 2013a) and good inter-rater
Table 2. Types of comorbidities and CGA characteristics comparison between cohorts
Whole cohort GI subgroup
Control %
(N¼70)
Intervention %
(N¼65) P-value
Control %
(N¼33)
Intervention %
(N¼41) P-value
Cardiac (including IHD, valve disease,
arrhythmia, CCF)
27.9 (19/68) 26.2 (17/65) 0.817 29.0 (9/31) 24.4 (10/41) 0.658
IHD 10.3 (7/68) 15.4 (10/65) 0.379 12.9 (4/31) 17.1 (7/41) 0.747
Arrhythmia 16.2 (11/68) 12.3 (8/65) 0.524 12.9 (4/31) 7.3 (3/41) 0.454
Hypercholesterolaemia 23.5 (16/68) 24.6 (16/65) 0.884 19.4 (6/31) 19.5 (8/41) 0.987
Hypertension 47.1 (32/68) 50.8 (33/65) 0.669 54.8 (17/31) 51.2 (21/41) 0.761
Stoke 8.8 (6/68) 4.6 (3/65) 0.493 3.2 (1/31) 4.9 (2/41) 1.000
Non-stroke neurological 7.4 (5/68) 10.8 (7/65) 0.492 6.5 (2/31) 7.3 (3/41) 1.000
Vascular disease 7.4 (5/68) 7.7 (5/65) 1.000 9.7 (3/31) 9.8 (4/41) 1.000
DM/glucose intolerance 13.2 (9/68) 27.7 (18/65) 0.038 9.7 (3/31) 24.4 (10/41) 0.108
Respiratory disease 22.1 (15/68) 15.4 (10/65) 0.325 22.6 (7/31) 12.2 (5/41) 0.242
CKD 8.8 (6/68) 6.2 (4/65) 0.745 6.5 (2/31) 7.3 (3/41) 1.000
MSK 25.0 (17/68) 30.8 (20/65) 0.458 19.4 (6/31) 34.1 (14/41) 0.165
GI disease 11.8 (8/68) 18.5 (12/65) 0.280 9.7 (3/31) 19.5 (8/41) 0.331
Psychiatry 1.5 (1/68) 9.2 (6/65) 0.059 0 7.3 (3/41) 0.254
Cognitive impairment 7.6 (5/66) 6.5 (4/62) 1.000 10.0 (3/30) 7.9 (3/38) 1.000
Delirium history 10.4 (7/67) 4.9 (3/61) 0.330 6.7 (2/30) 5.1 (2/39) 1.000
Depression 7.6 (5/66) 11.5 (7/61) 0.453 3.3 (1/30) 7.9 (3/38) 0.624
Falls 8.8 (6/68) 15.4 (10/65) 0.245 3.2 (1/1) 9.8 (4/41) 0.382
Visual impairment 10.4 (7/67) 14.3 (9/63) 0.506 16.1 (5/31) 15.0 (6/40) 1.000
Hearing impairment 4.4 (3/68) 13.8 (9/65) 0.058 3.2 (1/31) 12.2 (5/41) 0.227
Osteoporosis 5.9 (4/68) 13.8 (9/65) 0.122 6.5 (2/31) 19.5 (8/41) 0.171
Urinary incontinence 19.4 (13/67) 17.5 (11/63) 0.775 9.7 (3/31) 17.5 (7/40) 0.496
Bowel difficulty 20.9 (14/67) 16.1 (10/62) 0.487 16.1 (5/31) 17.9 (7/39) 0.841
Weight loss 58.2 (39/67) 56.5 (35/62) 0.840 45.2 (14/31) 60.5 (23/38) 0.203
ADL dependency 16.2 (11/68) 23.1 (15/65) 0.316 16.1 (5/31) 19.5 (8/41) 0.712
iADL dependency 29.9 (20/67) 20.3 (13/64) 0.209 30.0 (9/30) 12.5 (5/40) 0.070
Poor mobility 13.6 (9/66) 14.8 (9/61) 0.857 6.7 (2/30) 10.5 (4/38) 0.687
Difficulty with exercise 50.0 (34/68) 47.5 (29/61) 0.780 32.3 (10/31) 43.6 (17/39) 0.333
Lives alone 35.3 (24/68) 23.1 (15/65) 0.122 35.5 (11/31) 24.4 (10/41) 0.305
Difficulty with family life 23.1 (15/65) 8.1 (5/62) 0.020 10.3 (3/29) 5.1 (2/39) 0.644
Difficulty with social activities 37.3 (25/67) 19.4 (12/62) 0.024 23.3 (7/30) 15.4 (6/39) 0.403
No care available 13.4 (9/67) 4.8 (3/63) 0.088 9.7 (3/31) 5.1 (2/39) 0.649
No emotional support 0 1.5 (1/65) 0.489 0 2.4 (1/41) 1.000
Limiting pain 12.1 (8/66) 18.0 (11/61) 0.351 17.2 (5/29) 15.4 (6/39) 1.000
Sleep difficulty 14.7 (10/68) 27.4 (17/62) 0.074 19.4 (6/31) 17.9 (7/39) 0.881
Polypharmacy (5þ ) 31.7 (20/63) 50.8 (33/65) 0.029 32.1 (9/28) 48.8 (20/41) 0.169
Admitted 61.8 (42/68) 53.8 (35/65) 0.355 51.6 (16/31) 43.9 (18/41) 0.516
Abbreviations: ADL¼ activity of daily living; CCF¼ congestive cardiac failure; CGA¼ comprehensive geriatric assessment; CKD¼ chronic kidney disease; DM¼diabetes mellitus;
GI¼gastrointestinal; iADL¼ instrumental activities of daily living; IHD¼ ischaemic heart disease; MSK¼musculoskeletal. Note: All percentages are calculated excluding missing data.
Bold highlights those numbers reaching statistical significance for differences between the control and intervention groups.
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reliability (k 0.80) for risk assessment (Kalsi et al, 2014b). Other
studies have also demonstrated feasibility of self-reported screening
tools; a US study showed completion rates of 98% and mean
completion time of 15min (Hurria et al, 2007).
Nearly 300 intervention plans were made to investigate/modify/
support comorbidities and CGA needs for the 65 intervention
participants. Intervention plans were made for comorbidities (e.g.
cardiac disease, diabetes), CGA issues (e.g. bladder, nutrition,
medication reviews), symptoms (e.g. fatigue, pain) and in response
to abnormal tests, a finding consistent with others (Caillet et al,
2011; Chaibi et al, 2011). A French study demonstrated that
geriatrician-delivered CGA led to a number of interventions,
including 69.9% nutritional, 30.7% medication changes and further
investigations for 54.9% (Caillet et al, 2011). A chemotherapy-
specific study demonstrated that 122 patients required 227
intervention plans in five target intervention domains (nutrition,
depression, cognition, polypharmacy and social interventions); 81
required actions forZ2 of the target domains (Chaibi et al, 2011).
Table 3. Interventions to the intervention cohort
Intervention domain
Examples of intervention plans (below are examples, intervention plans not restricted
to the below)
Intervention group
% (N¼65)
Fatigue Investigation and/or treatment of thyroid disease, anaemia, treatment of poor nutrition, mood/anxiety,
provision of advice/information on coping strategies, adjusting contributing medications
49.2 (32/65)
Anaemia Treatment of iron/B12/folate deficiency anaemia (including with intravenous iron, oral supplements and
blood transfusions)
43.1 (28/65)
Nutrition Dietitian referral, provision of nutritional supplements, plan for needed dentures, referral for home meal
delivery, appetite stimulants
36.9 (24/65)
Plan in response to an
abnormal test
Replacement of vitamins (e.g. vitamin D), medication changes in response to electrolyte abnormalities
(e.g. diuretics and low sodium), arranging endoscopy in unexplained significant iron deficiency
35.4 (23/65)
Bladder Investigation and management of incontinence – for example, provision of pelvic floor exercises, bladder
retraining exercise, double voiding technique. Adjusting modifiable factors (e.g. drugs, lifestyle
exacerbators, atrophic vaginitis, retention), medical treatment of detrusor instability
Treatment of benign prostatic hypertrophy, treatment of urine infections, arranging trial without catheters
32.3 (21/65)
Cardiac Optimisation of IHD medications where relevant (e.g. aspirin, increasing anti-anginals), pacemaker
organisation, investigation of previously undiagnosed cardiac disease (e.g. echo, stress test, 24 h tape)
24.6 (16/65)
Pain Alteration to analgesia to optimise pain control 23.1 (15/65)
Diabetes intervention Adaptation to diabetic medications, pre-emptive planning for changes to medications during treatment
(e.g. plan for high glucose when steroids, or low glucose if expected reduced oral intake), arrange
monitoring (general practice, district or diabetic nurse), arranging needed equipment, for example, blood
glucose monitoring machine, arranging chiropody for diabetic foot risk
21.5 (14/65)
Medication change Reduction in unnecessary polypharmacy, adjusting antihypertensives in over/undertreated, adjusting
b-blockers in overtreated
18.5 (12/65)
HTN Adjusting antihypertensives (reducing or increasing). Pre-emptive planning for low blood pressure during
chemotherapy
16.9 (11/65)
Bowels Treatment of constipation, provision of anal sphincter exercises in faecal incontinence, management of
diarrhoea
16.9 (11/65)
Social Referral to social services, district nurse referrals, occupational therapy assessment for equipment needs,
provision of information on transport support and referrals for financial support
15.4 (10/65)
Postural hypotension Adjustment to causative medications, lifestyle advice (increase fluids, reduce caffeine), pre-emptive plans for
exacerbating toxicities (e.g. diarrhoea)
13.8 (9/65)
Renal Reduction in renal toxic medications if required (e.g diuretics), vitamin D replacement, measurement of
urine:creatinine ratio if relevant
12.3 (8/65)
MSK Management of arthritis pain (medications, TENS), treatment of osteoporosis 12.3 (8/65)
Falls Identify and management plan for contributing factors (e.g. adapt medications, organise any necessary
investigations (e.g. 24 h tape), physiotherapy referrals for strength and balance training, occupational
therapy referrals for equipment needs or home falls risk assessment
12.3 (8/65)
Mood Adjusting/starting antidepressants, referral for counselling 10.8 (7/65)
Referral to specialist Referral to cardiologist if significant reversible ischaemia requiring immediate treatment, dermatology for
treatment of basal cell carcinoma, palliative care referrals
10.8 (7/65)
Memory Memory clinic referral if significant cognitive impairment, assisting with mental capacity assessment,
identifying and treating any exacerbating factors (e.g. mood, medications), identifying delirium risk and
pre-emptive strategies to manage delirium±reduce risk
9.2 (6/65)
Respiratory Adapting relevant medications (e.g. inhalers, treatment of exacerbations), organising any needed
investigations (e.g. spirometry), smoking cessation referral and nicotine replacement, referral for pulmonary
rehabilitation
9.2 (6/65)
Hearing Referral to audiology, treatment of significant wax±referral for microsuctioning 6.2 (4/65)
Peripheral neuropathy Treatment of contributors (B12 deficiency) 6.2 (4/65)
Sleep Advice around lifestyle contributors (sleep hygiene, caffeine), adjusting exacerbating medications
(e.g. diuretics), management of other contributors, for example, mood
3.1 (2/65)
Vision Referral for visual aids/assessment 4.6 (3/65)
Abbreviations: HTN¼ hypertension; IHD¼ ischaemic heart disease; MSK¼musculoskeletal; TENS¼ transcutaneous electrical nerve stimulation. Note: All percentages are calculated excluding
missing data.
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To the authors knowledge, this is the first study examining the
impact of geriatrician-delivered CGA interventions to optimise
chemotherapy tolerance and reduce toxicity in older people with
cancer. Despite the robust evidence base for CGA in other settings
(Stuck et al, 1993; Elliot et al, 1996; Vidan et al, 2005; Harari et al,
2007; Ellis et al, 2011a, b; Gonzalez Montalvo et al, 2011), this has
been little applied to the chemotherapy setting. Studies investigating
chemotherapy tolerance and toxicity have focussed on GA screening
tools rather than CGA. GA screening tools have demonstrated utility
in predicting chemotherapy toxicity, although studies vary as to
which particular GA domains are associated with toxicity
(Extermann et al, 2011; Hurria et al, 2011; Hamaker et al, 2012),
and others have demonstrated no associations (Hamaker et al, 2012).
The findings of this study are generalisable to a variety of
tumour types and chemotherapy regimens with/without radio-
therapy. Our population was well matched to those previously
reported indicated by the similar grade 3þ toxicity rate in our
control group to the existing literature (Hurria et al, 2011). The
population studied included inner city and suburban residents and
was generalisable within NHS England.
This study, however, has limitations. The small sample size may
have contributed to nonsignificant results. As a comparative cohort
study, there is the potential for bias which may be minimised with
a randomised controlled trial design. However, differences between
the groups were identified, examined and adjusted for statistically.
There was a higher number of comorbidities in the intervention
group which may represent increased detection by the geriatrician.
However, the corresponding higher polypharmacy would indicate
that this group was genuinely more comorbid yet still had better
outcomes. There was also a difference in the spread of tumour
types between the groups. However, the improved outcomes in the
intervention group held true in the homogenous GI subgroup.
More patients in the intervention group also started at a reduced
dose at the outset that may reflect their higher comorbid burden.
The most common documented reason for initial dose reductions
in the intervention group was comorbidity. It may also reflect the
influence of CGA on decision making, facilitating individualised
treatment plans. Comprehensive geriatric assessment demon-
strated influence on decision making in 62.5% in previous work
related to this intervention study (Kalsi et al, 2013b). Similarly,
CGA has demonstrated influence on decision making in 20.8–49%
in France (Caillet et al, 2011; Chaibi et al, 2011).
The higher reduced dose at the outset in the intervention
group did not adversely affect disease control at 6 months
(identified in further analysis). In addition, tolerance and toxicity
outcomes remained statistically significant after adjustment for this
initial dose reduction. Adapted regimens have been shown not to
adversely affect outcomes in other studies. However, the follow-up
period for this study was 6 months. Longer follow-up would be
required to evaluate the longer-term impact of these initial dose
reductions on disease control.
This study also included a number of different chemotherapy
regimens. Chemotherapy type was not adjusted for, thus the results
should be interpreted with caution. There is no standard accepted
method for adjusting for chemotherapy type. The MAX2 index has
been previously developed for this purpose (Extermann et al, 2002)
and validated in trial participants (Extermann et al, 2004).
However, we did not apply the MAX2 to this study for a number
of reasons including (a) differences in definition of severe toxicity,
(b) the validation study used clinical trials participants only, thus
likely ‘fitter’ than the more heterogeneous cohort of this study and
(c) the validation study included fewer tumour types, metastatic/
advanced disease only and fewer treatment regimens, and thus
differed from our study population. However, in our study we
identified there were no differences between the groups in terms of
mono- and polychemotherapy between the groups. In addition, the
homogenous GI subgroup analysis served both to evaluate whether
the outcomes held true not only to tumour type but also in a group
who would thus also better matched in terms of the types of
chemotherapy regimens received. The positive outcomes remained
true in this subgroup analysis.
There is a need for clinical practice to evolve in response to the
changing needs of the population presenting to cancer services.
Issues identified through CGA are potentially modifiable through
intervention. Clinical trials evaluating the impact of CGA
interventions on chemotherapy tolerance are needed. Oncology
studies should shift their focus from GA tools towards the
interventional CGA clinical process, as highlighted in the recent
SIOG consensus (Wildiers et al, 2014), and this study could serve
to inform future statistical power.
This study would also add support to the recommendations
from the recent UK Department of Health report ‘Cancer Services
Coming of Age’ (Department of Health, 2012b)) to medically
optimise older people for cancer treatment. This, in part, could be
delivered by increasing geriatrics skills within oncology training. In
some areas of the world curricula have developed (Cohen, 1997;
Muss et al, 2005), whereas others are yet to make curricula change
with resulting lack of trainee confidence in managing older people
(Kalsi et al, 2013c).
The service model of CGA delivered via geriatrician liaison
was evaluated. Although hospitals in the United Kingdom
predominantly have both specialists working in the same
hospital, formal geriatric-oncology liaison services are rarely
resourced. Comprehensive geriatric assessment may not need to
be delivered by geriatricians. Protocolised intervention plans
facilitated remotely by geriatricians but delivered by nurses
(McCorkle et al, 2000) or other clinicians may be effective.
However, the UK Macmillan/Department of Health Older Persons
Pilot (of which this was one pilot site) demonstrated that
geriatrician liaison was the most effective way of delivering CGA
(Department of Health, 2012b)). Furthermore, the complexity of
some older people and the interaction between comorbidity, wider
issues (falls, continence, cognition) and function may be better
managed by geriatricians, as demonstrated in this study as well as
in other clinical settings (Stuck et al, 1993; Elliot et al, 1996; Vidan
et al, 2005; Harari et al, 2007; Ellis et al, 2011a,b; Gonzalez
Montalvo et al, 2011). This study provides some support to the
value of developing and sustaining such services for older people
with cancer.
Geriatrician input is being delivered in a few specialist geriatric
oncology centres across the world (e.g. France, United States). It is
perhaps time for this practice to become more widespread, with
more consistent inclusion of the geriatrician in the cancer
multidisciplinary team. The focus has to be on improving patient
Table 4. Prevalence of most common grade 3þ toxicities
Control %
(N¼70)
Intervention %
(N¼65) P-value
Neutropenia 20.0 (14/70) 14.1 (9/64) 0.363
Fatigue 12.5 (8/64) 12.9 (8/62) 0.946
Anaemia 14.3 (10/70) 4.7 (3/64) 0.061
Lymphopenia 12.9 (9/70) 7.8 (5/64) 0.340
Infection 8.6 (6/70) 3.1 (2/64) 0.278
Dehydration 7.1 (5/70) 3.1 (2/64) 0.444
Febrile neutropenia 5.7 (4/70) 4.7 (3/64) 1.000
Thrombocytopenia 4.3 (3/70) 4.7 (3/64) 1.000
Nausea 4.3 (3/70) 3.1 (2/64) 1.000
Diarrhoea 4.5 (3/67) 1.6 (1/64) 0.620
Peripheral neuropathy 4.3 (3/70) 0 0.246
Note: All percentages are calculated excluding missing data.
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factors to improve chemotherapy tolerance and clinical outcomes
for older people with cancer.
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